Ardelyx

Yahoo Finance • 20 days ago

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical need... Full story

Yahoo Finance • 26 days ago

Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end

Earnings Call Insights: Ardelyx (ARDX) Q1 2026 MANAGEMENT VIEW * “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding t... Full story

Yahoo Finance • 27 days ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) * Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) * Roku (ROKU [https://seekingalpha.com/symbol/ROKU]) * Twilio... Full story

Yahoo Finance • last month

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet... Full story

Yahoo Finance • 2 months ago

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Michael Raab, President & CEO of Ardelyx(NASDAQ:ARDX), reported a sale of 41,666 shares of Common Stock for a transaction value of approximately $243,000 on March 16, 2026, according to a SEC Form 4 filing. Transaction summary Metric Val... Full story

Yahoo Finance • 3 months ago

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

On Feb. 24, 2026, Ardelyx(NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct)... Full story

Yahoo Finance • 4 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 4 months ago

Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list. TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.... Full story

Yahoo Finance • 6 months ago

BTIG Maintains a Buy on Ardelyx, Inc (ARDX)

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earli... Full story

Yahoo Finance • 7 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 7 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH®... Full story

Yahoo Finance • 7 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studiesdemonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic hea... Full story

Yahoo Finance • 7 months ago

Ardelyx appoints Sue Hohenleitner as CFO

* Ardelyx (NASDAQ:ARDX [https://seekingalpha.com/symbol/ARDX]) announced on Monday the appointment [https://seekingalpha.com/pr/20263197-ardelyx-appoints-experienced-finance-executive-sue-hohenleitner-as-chief-financial-officer] of Sue H... Full story

Yahoo Finance • 7 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 7 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 8 months ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 9 months ago

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif., August 12, 2025--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William... Full story

Yahoo Finance • 10 months ago

Ardelyx raises 2025 IBSRELA revenue guidance to $250M–$260M amid sustained demand growth

Earnings Call Insights: Ardelyx (ARDX) Q2 2025 MANAGEMENT VIEW * Michael G. Raab, President and CEO, emphasized the company's strong quarter, stating "We generated $97.7 million in total revenue, representing 33% year-over-year growth,... Full story

Yahoo Finance • 10 months ago

Earnings call transcript: Ardelyx Q2 2025 beats earnings expectations

Ardelyx Inc (ARDX) reported its Q2 2025 earnings on August 4, revealing a notable earnings surprise. The company posted a net loss of $0.08 per share, beating analysts’ expectations of a $0.13 loss. Revenue reached $97.7 million, surpassin... Full story

Yahoo Finance • 10 months ago

Which stocks are moving after the closing bell on Monday?

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ADAP [https://www.... Full story